目的：对地西他滨联合CAG、微移植治疗老年急性髓系白血病进行临床分析。方法：将2015年1月至2016年7月我院收治的80例老年急性髓系白血病患者随机分为观察组与对照组，各40例，其中对照组接受地西他滨联合CAG治疗，观察组在对照组基础上联合微移植治疗。对比两组临床疗效、不良反应发生率、生存率、微小残留病及WT1基因含量。结果：观察组治疗总有效率为75.0%，对照组为50.0%，两组患者临床疗效差异具有统计学意义（χ²=6.572，P=0.037 4）。观察组不良反应发生率为27.50%，对照组为22.50%，两组患者不良反应发生率比较差异无统计学意义（χ²=0.266 7，P=0.605 6）。观察组与对照组的2年无白血病生存率分别为49.8%和25.2%（P=0.044），2年总生存率分别为54.2%和31.7%（P=0.069）。观察组低水平微小残留病例数及WT1基因低表达病例数均多于对照组，且差异具有统计学意义（P<0.05）。结论：地西他滨联合微移植是一种安全有效的巩固方案，适用于老年急性髓系白血病患者。

[1] BOSSHARD R,O'REILLY K,RALSTON S,et al.Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia[J].Cancer Treat Rev,2018,69(1):224-232.
[2] LOH K P,KLEPIN H D.Geriatric assessment in older patients with acute myeloid leukemia[J].Cancers (Basel),2018,10(7):E225-227.
[3] BUCCISANO F,DILLON R,FREEMAN S D,et al.Role of minimal (Measurable) residual disease assessment in older patients with acute myeloid leukemia[J].Cancers (Basel),2018,10(7):E215-219.
[4] BELL J A,GALAZNIK A,HUELIN R,et al.Effectiveness and safety of therapeutic regimens for elderly patients with acute myeloid leukemia:a systematic literature review[J].Clin Lymphoma Myeloma Leuk,2018,18(7):e303-e314.
[5] HU X,FU W,WANG L,et al.HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia[J].Oncotarget,2016,7(3):3623-3634.
[6] JIN J,CHEN J,SUO S,et al.Low-dose cytarabine,aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia[J].Leuk Lymphoma,2015,56(6):1691-1697.
[7] 张素芬,马明信,沈志祥,等.关于WHO造血系统髓系肿瘤分类方案的研讨[J].中国实用内科杂志,2003,23(3):129-143.
[8] 邓蕾,田培军,朱卫民.急性白血病化疗后不同时期应用粒细胞集落刺激因子的疗效对照研究[J].海南医学院学报,2014,20(6):789-791.
[9] O'DONNELL MR,TALLMAN MS,ABBOUD CN,et al.Acute myeloid leukemia,version 3.2017,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2017,15(7):926-957.
[10] LIPOF J J,LOH K P,O'DWYER K,et al.Allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia[J].Cancers (Basel),2018,10(6):E179-183.
[11] YAMADA K,FURUSAWA S,SAITO K,et al.Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:a pilot study[J].Leukemia,1995,9(1):10-14.
[12] MINAKATA D,FUJIWARA S,ITO S,et al.A low-dose cytarabine,aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia:a propensity score analysis[J].Leuk Res,2016,42(1):82-87.
[13] WANG Y,LI W,CHEN S,et al.Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation(8;21)[J].Leuk Res,2011,35(5):604-607.
[14] ZHU Y,ZHAO H,ZHANG X,et al.Decitabine before low-dose cytarabine-based chemotherapy cobined with human leukocyte antigen-mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia[J].Biol Blood Marrow Transplant,2017,23(5):830-835.
[15] 艾辉胜,孙琪云.《微移植治疗完全缓解期中青年急性髓细胞白血病的长期随访》解读[J].临床血液学杂志,2015,28(3):367-369.
[16] LOPEZ-MILLAN B,de la DIAZ G R,et al.IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q-AML[J].Oncoimmunology,2018,7(9):e1477460-e1477461.
[17] DOLSTRA H,FREDRIX H,van der MEER A,et al.TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2(CD158b) selectively lyse acute myeloid leukemia cells[J].Bone Marrow Transplant,2001,27(10):1087-1093.
[18] GOODYEAR O C,DENNIS M,JILANI N Y,et al.Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)[J].Blood,2012,119(14):3361-3369.